)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Akero Therapeutics
Akero Therapeutics (AKRO) investor relations material
Akero Therapeutics has been acquired by Novo Nordisk
Akero Therapeutics EGM 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.EGM 2025 summary2 Dec, 2025
Opening remarks and agenda
Meeting called to order at 11:00 A.M. Eastern Time, with rules of conduct posted on the web portal.
Inspector of Election appointed and oath filed with meeting minutes.
Notice, proxy statement, and affidavit of mailing made available to all stockholders.
Quorum confirmed with majority of outstanding shares present or represented by proxy.
Specific resolutions to be voted on
Adoption of the Agreement and Plan of Merger with Novo Nordisk A/S and NN Invest Sub Incorporated, including a Contingent Value Rights agreement.
Advisory non-binding approval of compensation to named executive officers in connection with the merger.
Overview of voting outcomes
Merger proposal approved by majority of outstanding shares.
Compensation proposal also approved by majority of outstanding shares.
Adjournment proposal not presented as merger was approved.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Akero Therapeutics
- EFX delivers unprecedented fibrosis improvement in cirrhotic MASH, with pivotal data due by 2027.AKRO
BofA Securities 2025 Healthcare Conference - Merger proposal offers $54/share plus $6 CVR; board and advisors unanimously support approval.AKROProxy Filing
- Efruxifermin advances in NASH/MASH with strong efficacy, key data in 2025, and solid cash reserves.AKRO7th Annual Evercore ISI HealthCONx Healthcare Conference
- Efruxifermin delivers strong, sustained fibrosis improvement and is positioned for broad NASH use.AKROH.C. Wainwright 8th Annual NASH Virtual Conference
- Anticipated two-year F4 cirrhosis data could reshape the NASH/MASH market landscape.AKROJefferies London Healthcare Conference 2024
- Efruxifermin delivers unprecedented fibrosis improvement in NASH, advancing through phase III trials.AKROMorgan Stanley 22nd Annual Global Healthcare Conference
- Efruxifermin delivers fast, significant fibrosis improvement, with key F4 data due in Q1.AKROJefferies 2024 Global Healthcare Conference
- 50 mg EFX achieved significant and durable cirrhosis reversal and MASH resolution at 96 weeks.AKROStudy Result
- Efruxifermin shows durable fibrosis reversal and strong safety, with pivotal data expected by 2027.AKRO43rd Annual J.P. Morgan Healthcare Conference 2025
Akero Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Akero Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in developing innovative treatments for serious metabolic diseases with significant unmet medical needs. The company's primary focus is on its lead product candidate, efruxifermin (EFX), which is in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation and inflammation in the liver. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.